Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LipoNova GmbH
immatics biotechnologies GMBH aims to identify tumor-associated peptides by directly measuring their presence in cancer tissue and then creating cancer vaccines from combinations of the most prevalent peptides associated with a particular tumor. The Tuebingen-based firm's proprietary platform combines genomics, mass spectrometry and cell-based assay systems to offer better speed and precision than existing technologies.
Summarizing the month in European dealmaking.